Beijing Zhongyin Tech's ZVS101e Injection Listed as Breakthrough Therapy for Bietti’s Crystalline Dystrophy
On June 29, the official website of the Center for Drug Evaluation (CDE) announced that ZVS101e injection, developed by Beijing Zhongyin Technology Co., Ltd., has been included in the list of breakthrough therapy designations for the treatment of Bietti crystalline dystrophy (BCD).
This milestone represents a major breakthrough for ZVS101e injection, marking its transition from scientific theoretical validation to clinical application in humans. The clinical safety and efficacy results further demonstrate the outstanding clinical value of ZVS101e injection and its significant potential for future market launch.
On the other hand, Zhongyin Technology’s R&D platform has further strengthened its translational capabilities, spanning from early-stage research on disease therapeutic targets to the final application of therapeutic products, thereby positioning itself to make greater contributions to the treatment of genetic diseases in the future.
Beijing Zhongyin Technology Co., Ltd. is a pioneer in ophthalmic gene therapy and a national high-tech enterprise specializing in genetic diagnosis of inherited eye diseases and the development of gene therapy drugs. It is committed to providing patients with inherited eye diseases with "one-stop" services for precise diagnosis and treatment. Leveraging its diagnostic platform, Zhongyin Technology has established a database and large-scale cohorts for inherited eye diseases, summarized the mutation spectrum among Chinese patients, and identified therapeutic targets for drug development. On this basis, the company develops drugs with independent intellectual property rights, including gene replacement therapy and gene editing therapy, striving to achieve breakthroughs from "zero to one." Currently, it has established a comprehensive drug development system encompassing target screening, basic research, animal model validation, stem cell validation, AAV vector R&D and manufacturing, clinical trial operations, and regulatory submission for drug registration.
